Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00114439
Status:
COMPLETED
Last Update Posted:
2007-09-27
First Post:
2005-06-14
Brief Title:
Lithium Cannabis Withdrawal Study
Sponsor:
Sydney South West Area Health Service
Organization:
Sydney South West Area Health Service
Study Overview
Official Title:
An Open Label Trial of Lithium for the Management of Cannabis Withdrawal
Status:
COMPLETED
Status Verified Date:
2007-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood sleep hostility and aggression Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program
Detailed Description:
There are currently no accepted pharmacotherapies for the management of cannabis withdrawal A recent study by Cui et al 2001 investigated the effects and mechanism of lithium on cannabinoid withdrawal in rats The researchers found that lithium administration prevented the development of withdrawal symptoms and suggested that increased oxytocin secretion resulting from lithium dosing prevented the withdrawal syndrome from occurring Although caution should be exercised in generalising the results of an animal study preliminary results of a small pilot study in humans are consistent with the potential utility of lithium in the management of human cannabis withdrawal Zhang personal communication Furthermore human use of lithium is well established and the addition of a readily available drug such as lithium carbonate would be a useful clinical tool should it prove efficacious in a series of clinical trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UNSW HREC 04168 | None | None | None |